Getting the hang of through-hole soldering is tricky for those of us tinkering at home with our irons, spools, flux, and, sometimes, braids. It’s almost reassuring, then, to learn that through-hole soldering was also a pain for a firm that has made more than 60 million products with it. Raspberry Pi boards have a combination … Read more
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Update on the DrugSorb-ATR Regulatory Process Management reiterated that their De Novo DrugSorb-ATR submission continued to be in interactive review with FDA, that their Medical Device License application to Health Canada was in advanced review, and that they continue to expect regulatory decisions in … Read more
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization efforts and sales will be focused on recombinant serum albumin. Further down the road, additional proteins may be added including bovine albumin, bovine transferrin … Read more
This article is an on-site version of our Europe Express newsletter. Premium subscribers can sign up here to get the newsletter delivered every weekday and Saturday morning. Standard subscribers can upgrade to Premium here, or explore all FT newsletters Good morning. Upon arriving at the White House, Donald Trump signed orders to review “unfair trade … Read more
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On January 3, 2025, CytoSorbents (NASDAQ:CTSO) reported strong preliminary 4th quarter and full year 2024 financial results which exceeded our expectations. 4th quarter product revenue (excluding grant income) is estimated to be in the range of $9.0-$9.2 million, which is approximately 22% to 25% … Read more